PhRMA Statement on House Leadership’s “Partisan” Drug Pricing Proposal
WASHINGTON, D.C. (April 22, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after House Democratic leaders released their partisan drug pricing proposal:
“The American people want to end the pandemic, get the economy back on track and make health care more affordable and predictable. Instead, House leaders have introduced the same old divisive drug pricing proposal that will put more barriers between patients and their medicines. It will also destroy an estimated one million American jobs, cede our leadership in life sciences, and stifle the development of new treatments, while failing to address the broader challenges facing patients. It’s unfortunate House leaders are reintroducing this partisan bill, particularly as we continue to fight a pandemic. The American people deserve a better approach, and that’s why we put forward a set of ideas that will lower what patients pay at the pharmacy and protect access to medicines and future innovation. The status quo isn’t working, and we’re willing to do our part to deliver the kind of responsible solutions all patients need.”
To learn more about our solutions for lowering patients’ drug costs, visit phrma.org/betterway.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including an estimated $91.1 billion in 2020 alone.